Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Hold" by Analysts
Nkarta, Inc. (NASDAQ:NKTX) has an average "Hold" recommendation from five brokerages, with an average 12-month price target of $11.33. The company recently missed its EPS estimates and its CEO, Paul J. Hastings, sold 26,046 shares in January. Institutional investors hold a significant portion of the stock, while its shares currently trade around $2.32.
[EFFECT] Nkarta, Inc. SEC Filing
This article reports on an SEC filing by Nkarta, Inc. (NKTX) for a Form EFFECT, which became effective on April 3, 2026, at 4:00 P.M. The filing is identified as an S-3 form related to shelf registration. The article also provides Nkarta's stock overview, recent news, and other SEC filings.
Nkarta (NASDAQ: NKTX) launches $100M ATM shelf via Stifel as sales agent
Nkarta, Inc. (NASDAQ: NKTX) has filed a prospectus to offer up to $100 million in common stock through an "at-the-market" (ATM) program, with Stifel, Nicolaus & Company, Incorporated acting as the sales agent. The offering allows Nkarta to sell shares at current market prices, providing flexibility for capital raises. Proceeds from the offering are intended for research, development, manufacturing of product candidates, advancing its NK cell therapy platform, increasing working capital, funding capital expenditures, and general corporate purposes.
NKTX Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Nkarta Inc (NKTX), showing a "Strong Buy" consensus based on various technical indicators and moving averages. Key metrics like RSI, MACD, and support/resistance levels are detailed, along with frequently asked questions about the stock's current technical outlook.
NKTX PE Ratio & Valuation, Is NKTX Overvalued
Nkarta Inc (NKTX) is currently considered to be in the "Fair zone" based on its forward PS ratio of 0.00 compared to its five-year average of -3.85. The article details various valuation metrics for NKTX, including its Price-to-Book ratio, Free Cash Flow yield, and a comparison of its P/S ratio against competitor averages, noting that a robust revenue growth figure is needed to justify its premium.
Nkarta (NASDAQ:NKTX) Price Target Lowered to $12.00 at Mizuho
Mizuho analysts have lowered their price target for Nkarta (NASDAQ:NKTX) from $14.00 to $12.00, while maintaining an "outperform" rating. This new target suggests a potential upside of approximately 467.91% from Nkarta's previous closing price. The company reported negative earnings per share (EPS) of -$0.37, missing analyst estimates, and currently holds a consensus "Hold" rating among analysts with an average target price of $11.33.
HC Wainwright Forecasts Nkarta's Q1 Earnings (NASDAQ:NKTX)
HC Wainwright has revised its Q1 2026 earnings per share estimate for Nkarta (NASDAQ:NKTX) down to ($0.40) from ($0.34), also lowering forecasts for subsequent quarters and fiscal years up to 2030. This adjustment suggests a weaker near-term outlook due to anticipated higher costs or extended development timelines. Despite the revised estimates and a mixed analyst sentiment, Nkarta's stock currently holds a consensus "Hold" rating with an average price target of $12.00, significantly higher than its current trading price of $2.06.
Nkarta (NASDAQ:NKTX) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen has downgraded Nkarta (NASDAQ:NKTX) from a "hold" to a "sell" rating, despite the broader Street consensus remaining a "Hold" with an average target price of $12.00. The downgrade follows Nkarta reporting a Q1 EPS of ($0.37), missing estimates, and comes after CEO Paul J. Hastings sold a portion of his shares. The biotechnology company, specializing in NK cell therapies for cancer, currently trades near $2.06 with a market cap of approximately $153 million, and its stock has experienced a 52-week range of $1.42–$2.81.
TD Cowen Maintains Nkarta(NKTX.US) With Buy Rating
TD Cowen has reiterated its Buy rating on Nkarta (NKTX.US). This endorsement suggests the firm's continued confidence in the company's stock performance. Investors will likely view this as a positive signal regarding Nkarta's outlook.
Nkarta Launches $100 Million At-the-Market Stock Offering
Nkarta Inc. has initiated an at-the-market equity offering of up to $100 million of its common stock through a sales agreement with Stifel, Nicolaus & Company. This offering, detailed in an S-3 shelf registration, provides Nkarta with flexible access to capital to support its business needs. Analysts currently rate NKTX stock as a Hold with a $2.00 price target, while Spark, TipRanks' AI Analyst, views it as Neutral due to weak financial performance and bearish technical indicators.
NKTX (Nkarta) PB Ratio : 0.51 (As of Mar. 26, 2026)
This article from GuruFocus.com analyzes Nkarta Inc.'s (NKTX) Price-to-Book (PB) Ratio, which stands at 0.49 as of March 27, 2026. The ratio is significantly lower than the Biotechnology industry median, indicating a potentially undervalued stock relative to its assets, though the company also carries 3 warning signs. The article explains the PB Ratio calculation, its historical trends for Nkarta, and compares it to industry peers.
Stifel reiterates Nkarta stock rating on trial enrollment progress
Stifel maintained its Buy rating and an $11.00 price target on Nkarta Inc. (NASDAQ:NKTX) shares. The firm is encouraged by the patient enrollment progress in the Ntrust-1/2 trials for NKX019 in autoimmune diseases, although uncertainties remain regarding the magnitude and duration of future data disclosures. Stifel believes data showing deep B cell depletion and subsequent healthy B cell reconstitution will improve visibility into clinical outcomes.
Nkarta Launches $100 Million At-the-Market Stock Offering
Nkarta (NKTX) has launched a $100 million at-the-market (ATM) stock offering with Stifel, Nicolaus & Company to provide flexible access to equity capital. This offering allows Nkarta to raise funds opportunistically to support its business operations and clinical development programs. The company's stock currently holds a "Hold" rating from analysts with a $2.00 price target, while TipRanks' AI Analyst, Spark, assesses NKTX as Neutral due to weak financial performance and bearish technical indicators.
Nkarta launches $100M at-the-market equity program with Stifel
Nkarta (NKTX) has initiated an at-the-market offering agreement with Stifel, allowing the company to sell up to $100 million of common stock. Nkarta will maintain control over the offering parameters, including timing and pricing, to manage dilution and the influx of proceeds. Stifel will act as the sales agent, utilizing various trading markets and potentially earning up to a 3% commission on gross proceeds.
Nkarta (NASDAQ: NKTX) launches $100M at-the-market stock sale plan
Nkarta (NASDAQ: NKTX) has initiated an at-the-market stock offering program, allowing it to sell up to $100 million in common stock through Stifel, Nicolaus & Company as its sales agent. The company will retain control over the sale parameters, including timing, volume, and minimum prices, and will pay Stifel a commission of up to 3% of the gross proceeds. This program is being executed under Nkarta’s existing Form S-3 registration statement and an accompanying prospectus supplement filed with the SEC.
Nkarta (NASDAQ: NKTX) launches $100M at-the-market program via $350M shelf
Nkarta, Inc. (NASDAQ: NKTX) has filed an S-3 shelf registration statement for up to $350 million in various securities, which includes an at-the-market (ATM) program of up to $100 million for common stock through Stifel, Nicolaus & Company, Incorporated. The proceeds from sales through this ATM program will be used for general corporate purposes, including funding research, development, and manufacturing of its product candidates, and increasing working capital. As of March 18, 2026, the company had 74,290,521 shares of common stock issued and outstanding.
Nkarta 2025 10-K: Net loss $104.1M, EPS $(1.41)
Nkarta reported a net loss of $104.1 million for the year ended December 31, 2025, with an EPS of $(1.41), and an operating loss of $122.0 million. The company implemented cost containment measures, workforce reductions, and strategically prioritized its NKX019 program, including advancing clinical trials and optimizing its manufacturing model. Nkarta expects its current cash and investments to support operations for at least 12 months, with plans to raise additional capital.
Nkarta (NASDAQ: NKTX) reports 2025 loss and extends cash runway to 2029
Nkarta, Inc. reported its fourth quarter and full-year 2025 financial results, showing a net loss of $104.1 million for the year. The company's cash, cash equivalents, and investments totaled $295.1 million as of December 31, 2025, which is projected to fund operations into 2029. Nkarta also highlighted continued clinical progress for its NKX019 autoimmune program, with initial clinical data expected to be presented at a medical conference in 2026.
Nkarta (NASDAQ:NKTX) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS
Nkarta (NASDAQ:NKTX) reported quarterly earnings of ($0.37) per share, missing consensus estimates by $0.05. Despite missing expectations, the stock rose by 3.9% to $2.13. Insider transactions included CEO Paul J. Hastings selling shares, while institutional investors have adjusted their holdings.
Nkarta (NKTX) to Release Earnings on Tuesday
Nkarta (NASDAQ:NKTX) is scheduled to release its Q4 2025 earnings before the market opens on Tuesday, March 31st, with analysts forecasting a loss of ($0.32) per share. The stock currently trades around $2.18, within a 52-week range of $1.31–$2.81, and has a market capitalization of $154.85 million. Insider selling by CEO Paul J. Hastings and significant institutional holdings activity have been noted, while analysts maintain a "Moderate Buy" consensus with a price target of $13.25.
If You Invested $1,000 in Nkarta, Inc. (NKTX)
This article analyzes the historical performance of investing $1,000 in Nkarta, Inc. (NKTX) over various periods, showing significant losses over 5 and 10 years but a gain over the last year. It also provides a detailed overview of Nkarta, Inc.'s focus on engineered natural killer (NK) cell therapies for autoimmune diseases, highlighting its key therapeutic candidate NKX019 and ongoing clinical trials. The company's scientific rationale, regulatory status, and risk considerations are discussed to offer a comprehensive profile for potential investors.
Nkarta Inc expected to post a loss of 32 cents a share - Earnings Preview
Nkarta Inc (NKTX) is projected to report an earnings loss of 32 cents per share. This financial forecast comes as part of an earnings preview. The information was provided by Reuters and Refinitiv.
NKTX Q4'25 Earnings: EPS estimate is (0.31) USD
Nkarta, Inc. (NKTX) is scheduled to release its Q4'25 earnings on March 19, with an estimated EPS of (0.31) USD and revenue of 0 USD. The article provides a table of past and estimated revenue and EPS figures, highlighting EPS surprises.
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Nkarta, Inc. (NASDAQ:NKTX) has received a consensus "Moderate Buy" rating from six brokerages, with an average one-year price target of $13.25 significantly above its current trading price. The company's shares opened at $2.43, down about 5.4%, giving it a market cap of $172.6 million. Insider Paul J. Hastings recently sold 26,046 shares, representing a 6.26% reduction in his position, while institutional investors and hedge funds hold a substantial 80.54% of the stock.
NKTX Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive overview of Nkarta, Inc.'s (NKTX) financial statements, including income statements, balance sheets, and cash flow statements, derived from SEC filings. It highlights key financial metrics for fiscal year 2024, such as $0 revenue, -$108.8M net income, and a low Piotroski F-Score, indicating weak financial health. The report also details the company's negative free cash flow, operating cash flow, and an estimated cash runway of approximately 3 months.
Nkarta to Participate in March Investor Conferences
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company focused on developing NK cell therapies for autoimmune diseases, announced its participation in two investor conferences in March 2026. The company will hold fireside chats at the TD Cowen 46th Annual Health Care Conference and the Leerink Global Healthcare Conference. Webcasts of both events will be available on Nkarta's website.
Nkarta to Participate in March Investor Conferences
Nkarta, Inc. announced its participation in two upcoming investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference and the Leerink Global Healthcare Conference. The clinical-stage biopharmaceutical company, focused on engineered natural killer cell therapies for autoimmune diseases, will present at fireside chats at both events. Webcasts of these presentations will be available on the Investors section of Nkarta's website.
Nkarta to Participate in March Investor Conferences
Nkarta, Inc., a clinical-stage biopharmaceutical company focused on engineered natural killer (NK) cell therapies for autoimmune diseases, announced its participation in two investor conferences in March 2026. The company will be present at the TD Cowen 46th Annual Health Care Conference and the Leerink Global Healthcare Conference, with webcast replays available on its investor relations website.
NKTX - Nkarta, Inc. Latest Stock News & Market Updates
This page provides investors and traders with the latest news and analysis for Nkarta, Inc. (NKTX), a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for autoimmune diseases. It aggregates company press releases and market updates, including clinical trial progress for NKX019, financial results, corporate restructuring, leadership changes, and participation in investor conferences. The page also includes historical news items and stock data for NKTX.
Tang Capital discloses 2.1% Nkarta (NKTX) ownership in Schedule 13G/A
Tang Capital Management and associated entities have filed an amended Schedule 13G, revealing a 2.1% beneficial ownership in Nkarta, Inc. (NKTX), totaling 1,480,823 shares. This investment is declared passive, with no intention to alter or influence company control. The ownership is based on 71,029,512 Nkarta shares outstanding as of November 5, 2025, and involves shared voting and dispositive power among the reporting entities.
Nkarta, Inc. (NASDAQ:NKTX) Receives Average Rating of "Moderate Buy" from Analysts
Nkarta, Inc. (NASDAQ:NKTX) has an average "Moderate Buy" rating from six analysts, with an average 12-month price target of $13.25 significantly above its current trading price of $1.97. The company is a clinical-stage biotechnology firm focused on off-the-shelf natural killer cell therapies for cancer. Recent insider selling by the CEO and institutional trading activity are noted, with institutions owning a significant portion of the stock.
Nkarta Insiders Make Handsome Sum Selling Stock At US$2.06 Per Share
Nkarta, Inc. (NASDAQ:NKTX) recently saw significant insider selling, with a large transaction by Paul Hastings at US$2.06 per share, below the current stock price of US$2.40. Over the past year, insiders have not purchased any shares, and recent selling activity totaled US$66k. This behavior, alongside minimal insider ownership (approximately US$770k), suggests caution for potential investors, despite the stock's recent 22% increase.
Nkarta (NKTX) president Nadir sells $11,693 in shares
Nkarta (NKTX) President Nadir Mahmood sold 5,649 shares of common stock for $11,693 to cover tax obligations related to Restricted Stock Units vesting. Following this, Mahmood directly owns 167,727 shares. The company is also advancing clinical programs for its NK cell therapy, NKX019, with Stifel adjusting its price target to $11 while maintaining a Buy rating.
Nkarta CEO Hastings sells $53,915 in NKTX stock By Investing.com
Nkarta CEO Paul J. Hastings sold 26,046 shares of NKTX stock worth $53,915 to cover tax obligations related to Restricted Stock Units vesting. Despite the sale, Hastings still directly owns 390,023 shares, and analysts maintain a bullish outlook on the company. Nkarta, a clinical-stage biotech company, recently announced positive clinical data for its NKX019 therapy and had its price target adjusted by Stifel from $12 to $11, while retaining a Buy rating due to accelerated trial enrollment.
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Moderate Buy" by Analysts
Nkarta, Inc. (NASDAQ:NKTX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $13.25. Insider selling by CEO Paul J. Hastings was reported, but institutional investors have shown mixed activity. The company is a clinical-stage biotech focusing on NK cell therapies for cancer.
Insider Selling: Nkarta (NASDAQ:NKTX) President Sells 5,649 Shares of Stock
Nkarta (NASDAQ:NKTX) President Nadir Mahmood recently sold 5,649 shares of the company's stock for $2.07 per share, reducing his total stake by 3.26%. The sale, totaling $11,693.43, leaves him with 167,727 shares valued at approximately $347,194.89. Despite this insider selling, Nkarta maintains a "Moderate Buy" consensus rating from analysts with an average price target of $13.25.
Insider Selling: Nkarta (NASDAQ:NKTX) CEO Sells 26,046 Shares of Stock
Nkarta (NASDAQ:NKTX) CEO Paul Hastings sold 26,046 shares of the company's stock on January 15th at an average price of $2.07, totaling $53,915.22. This sale reduced his stake by 6.26%, leaving him with 390,023 shares valued at approximately $807,347.61. The biopharmaceutical company's shares are trading around $2.04, and analysts maintain a "Moderate Buy" rating with an average target price of $13.25.
Nkarta CEO Hastings sells $53,915 in NKTX stock
Nkarta, Inc. CEO Paul J. Hastings sold 26,046 shares of common stock valued at $53,915 on January 15, 2026, to cover tax withholding obligations. The company, trading at $2.04 per share, holds more cash than debt, though it is burning through reserves. Analysts maintain a bullish outlook despite the recent transaction, with Stifel adjusting its price target to $11.00 while keeping a Buy rating.
Nkarta (NKTX) president Nadir sells $11,693 in shares
Nkarta, Inc.'s President, Nadir Mahmood, sold 5,649 shares of common stock for $11,693 to cover tax obligations. This sale occurred on January 15, 2026, and Mahmood now directly owns 167,727 shares. The company is also set to present new clinical data for its NK cell therapy, NKX019, and Stifel adjusted its price target for Nkarta, maintaining a Buy rating.
Nkarta CEO Hastings sells $53,915 in NKTX stock
Nkarta CEO Paul J. Hastings sold 26,046 shares of NKTX common stock for $53,915 on January 15, 2026, to cover tax obligations. The clinical-stage biotech company, currently trading at $2.04, is considered undervalued by InvestingPro despite having strong liquidity and a 10.27% year-to-date return. Nkarta also recently announced positive clinical data for its NKX019 therapy and received an adjusted price target of $11.00 from Stifel, which maintained a Buy rating.
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts
Nkarta, Inc. (NASDAQ:NKTX) has received an average rating of "Moderate Buy" from analysts, with six firms covering the stock, resulting in an average 1-year target price of $13.25. The company currently has a market capitalization of $130.7 million, and institutional investors hold approximately 80.54% of its shares. Recent institutional activity shows various funds increasing their positions in Nkarta, reflecting a notable level of investor interest.
Nkarta (NASDAQ:NKTX) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded Nkarta (NASDAQ:NKTX) from a "sell" to a "hold" rating, contributing to a "Moderate Buy" consensus and an average target price of $13.25 among analysts. Despite mixed analyst coverage, Nkarta showed strong institutional ownership and beat Q3 EPS estimates. The company, a clinical-stage biotechnology firm specializing in NK cell therapies for cancer, has a market cap of $127.14 million.
Nkarta Shares Show Signs of Finding a Floor
Nkarta Inc.'s stock saw a 1.70% gain with significantly increased trading volume, suggesting renewed investor interest after a period of selling pressure. The company's NK cell therapy program is progressing, with a new lymphodepletion regimen achieving complete B-cell depletion in patients. Despite a mixed technical outlook, Nkarta's strong financial position and "Moderate Buy" analyst consensus indicate potential upside.
Nkarta (NASDAQ:NKTX) Downgraded by Wall Street Zen to Sell
Wall Street Zen downgraded Nkarta (NASDAQ:NKTX) from a "hold" to a "sell" rating. Despite this PESSIMISTIC action, the consensus among analysts remains a "Moderate Buy" with a $13.25 price target. Nkarta reported Q3 EPS of -$0.29, beating estimates by $0.03, and institutional investors hold a significant portion of its shares.
NKTX: Robust I&I data expected next year, with accelerated enrollment and strong financial runway
Nkarta, Inc. (NKTX) anticipates robust data from its I&I program next year, following a delay to ensure strong results from an updated Flu/Cy regimen. The trial has improved enrollment and engagement, now utilizing a basket design across five indications. NKTX also has strong FDA support and a cash runway extending into 2029.
Nkarta, Inc. (NASDAQ:NKTX) Receives Average Recommendation of "Moderate Buy" from Analysts
Nkarta, Inc. (NASDAQ:NKTX) has an average "Moderate Buy" recommendation from six analysts, with a consensus 12-month target price of $13.25. The clinical-stage biopharmaceutical company is developing natural killer cell therapies, and its lead candidate, NKX019, is in Phase 1 trials for non-Hodgkin lymphoma and lupus nephritis. Nkarta recently reported better-than-expected EPS and has significant institutional investor interest.
Nkarta to Participate in Evercore Healthcare Conference
Nkarta, Inc. announced its participation in the Evercore 8th Annual Healthcare Conference on December 4, 2025, where it will host a fireside chat at 10:50 a.m. ET. The clinical-stage biopharmaceutical company is developing engineered natural killer (NK) cell therapies for autoimmune diseases. A webcast of the event will be available on the Investors section of Nkarta’s website, with a replay archived for approximately 90 days.
Nkarta to Participate in Evercore Healthcare Conference
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for autoimmune diseases, announced its participation in the Evercore 8th Annual Healthcare Conference. The company will present on December 4, 2025, at 10:50 a.m. ET via a fireside chat, with a webcast available on their investors section. Nkarta is advancing allogeneic, off-the-shelf NK cell therapies utilizing its cell expansion and cryopreservation platform along with proprietary cell engineering.
Nkarta (NASDAQ: NKTX) posts $316.5M cash; second NKX019 dose-escalation cohort underway
Nkarta (NASDAQ: NKTX) reported its Q3 2025 financial results, announcing $316.5 million in cash and investments, projected to fund operations into 2029. The company also announced that the second dose-escalation cohort for its NKX019 autoimmune program is now underway, following clearance from a combined independent Data Safety Monitoring Board (iDSMB). Initial data for NKX019 in multiple autoimmune indications is expected to be presented at a medical conference in 2026.
Nkarta (Nasdaq: NKTX) to join fireside chats at Stifel, TD Cowen Nov. 12–13
Nkarta (NKTX) announced its participation in two investor conferences in November 2025. The clinical-stage biopharmaceutical company will engage in fireside chats at the Stifel 2025 Healthcare Conference on November 12 and the TD Cowen Immunology & Inflammation Summit on November 13. Webcasts of both events will be available on Nkarta's investor website, with replays archived for 90 days.
